What are the signs and symptoms of insulinoma and how is it treated?

Insulinoma: Signs/Symptoms and Treatment

For suspected insulinoma, confirm diagnosis with the Whipple triad and a supervised fast, then proceed directly to surgical resection (enucleation or partial pancreatectomy) as this is curative in >90% of cases.

Clinical Presentation

Classic Whipple Triad (Diagnostic Hallmark)

The diagnosis requires all three components 1, 2:

1. Symptoms/signs of hypoglycemia during episodes
2. Documented low plasma glucose (<50 mg/dL) at time of symptoms
3. Complete symptom resolution when glucose normalized

Neuroglycopenic Symptoms (Most Common)

These occur during fasting states and include 3, 4:

• Loss of consciousness (68% of patients)
• Confusion and altered mental status
• Seizures (can masquerade as primary neurological disease 5)
• Vertigo/dizziness (56%)
• Visual disturbances

Sympathetic/Adrenergic Symptoms

• Diaphoresis/sweating (59% of patients 3)
• Tremors
• Palpitations

Critical Clinical Pitfall

Average diagnostic delay is 33.4 months 3. Many patients are misdiagnosed with neurological or psychiatric disorders and inappropriately treated with antiepileptics or antidepressants 4. Maintain high suspicion in any patient with recurrent hypoglycemic symptoms that improve with food intake, particularly if symptoms occur during fasting.

Diagnostic Approach

Step 1: Biochemical Confirmation

Perform a supervised prolonged diagnostic fast (up to 72 hours) 1. Document:

• Plasma glucose <55 mg/dL
• Elevated insulin levels during hypoglycemia
• Elevated C-peptide (men typically show higher levels 4)
• Inappropriately low β-hydroxybutyrate

Step 2: Tumor Localization

CT combined with MRI achieves 96.87% diagnostic accuracy 3. The algorithmic approach:

1. First-line imaging: CT and/or MRI of pancreas
2. If negative or equivocal: Endoscopic ultrasound (EUS) - sensitivity >90% with option for fine-needle aspiration 1, 4
3. For occult tumors: GLP-1 receptor PET/CT or PET/MRI (highly sensitive for seemingly occult insulinomas 2)
4. Invasive localization: Selective arterial calcium stimulation with hepatic venous sampling (>2-fold insulin increase confirms regionalization 1)

Most insulinomas are small (<2 cm), solitary, and evenly distributed between pancreatic head/neck (48.68%) and body/tail (51.32%) 3, 4.

Treatment Algorithm

Benign/Indolent Insulinoma (>90% of cases)

Surgical resection is the definitive curative treatment 1, 2:

• Enucleation is the procedure of choice (65.79% of cases) as a parenchyma-sparing approach 3
• Distal pancreatectomy for body/tail tumors when enucleation not feasible
• Curative in 90-94% of patients with 5-year survival of 94-100% 2, 6

Important surgical considerations 3:

• Average operative time: 216 ± 105 minutes
• Pancreatic fistula occurs in 53.95% (usually manageable)
• Pancreatic head/neck tumors have higher complication rates including bleeding (7.89% overall, all in head/neck cases)
• Intraoperative suturing of high-risk vessels recommended for head/neck lesions

Malignant/Aggressive Insulinoma (Rare)

The prime therapeutic objective is complete and lasting control of hypoglycemia 7:

Medical Management Algorithm 7:

1. First-line: Diazoxide OR Somatostatin analogues

   • Assess for complete symptomatic response (sCR)

2. Second-line (if intolerance or failure): Everolimus

   • Ideal for asymptomatic low tumor burden due to combined hyperglycemic and antitumoral effects 7
   • Alternative: Liver chemoembolisation for severe refractory hypoglycemia (emergency antisecretory action)

3. Third-line: Other antitumoral options based on tumor grade and progression:

   • Rapidly progressive G1-G2: Systemic chemotherapy first-line
   • Slowly progressive G1-G2: SMS analogues or PRRT
   • Stable disease, low volume: Surgery or locoregional options

Urgent Supportive Measures (Concurrent with Medical Treatment) 7:

• Fractionated enriched meals or enteral feeding
• Glucose perfusion via 1-2 central lines
• Specialist nursing and dietician involvement
• Patient/family education and anxiety management

Avoid Sunitinib

Do not use sunitinib in malignant insulinoma - despite antitumoral efficacy in pancreatic NETs, it carries risk of severe hypoglycemia 7.

Follow-Up

• Benign insulinoma post-resection: No surveillance needed 7
• Uncertain prognosis/incomplete resection: Clinical exam and abdominal MRI every 6 months to 2 years for 10 years, then every 2-5 years lifelong 7
• Malignant insulinoma: Assess at 3 months post-treatment, then every 6 months if stable, monitoring nutritional status, psychological impact, and central line care 7